Editas Medicine, INC 8-K filings

Editas Medicine held its annual meeting on May 30, 2024, electing three Class II directors, approving executive compensation on an advisory basis, and ratifying Ernst & Young as its auditor.

Editas Medicine announced its first quarter 2024 financial results, highlighted by progress in clinical trials for sickle cell disease and beta-thalassemia, and a strong financial position extending into 2026.

Editas Medicine announced its fourth quarter and full year 2023 financial results, highlighting progress in its clinical programs and a strong financial position.